List of Excipients in Branded Drug NAFCILLIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Baxter Healthcare Corporation	NAFCILLIN	nafcillin	0338-1019	DEXTROSE MONOHYDRATE
Baxter Healthcare Corporation	NAFCILLIN	nafcillin	0338-1019	HYDROCHLORIC ACID
Baxter Healthcare Corporation	NAFCILLIN	nafcillin	0338-1019	SODIUM HYDROXIDE
Baxter Healthcare Corporation	NAFCILLIN	nafcillin	0338-1019	TRISODIUM CITRATE DIHYDRATE
Baxter Healthcare Corporation	NAFCILLIN	nafcillin	0338-1019	WATER

Generic Drugs Containing NAFCILLIN

Company	Ingredient	NDC	Excipient
Hospira Inc	nafcillin	0409-3713	SODIUM CITRATE
Hospira Inc	nafcillin	0409-3715	SODIUM CITRATE
Sandoz Inc	nafcillin	0781-3124	SODIUM CITRATE
Sandoz Inc	nafcillin	0781-3126	SODIUM CITRATE
Sandoz Inc	nafcillin	0781-9124	SODIUM CITRATE
Sandoz Inc	nafcillin	0781-9126	SODIUM CITRATE
Heritage Pharmaceuticals Inc d/b/a/ Avet Pharmaceuticals Inc	nafcillin sodium	23155-906	SODIUM CITRATE

What are the Most Frequently-Used Excipients in NAFCILLIN?

# Of NDCs	Excipient
21	SODIUM CITRATE

Nafcillin Excipient Strategy and Commercial Opportunities

Last updated: August 11, 2026

Nafcillin is an established antistaphylococcal penicillin used primarily as intravenous therapy for serious methicillin-susceptible Staphylococcus aureus infections. Its commercial opportunity is concentrated in injectable product design, hospital supply reliability, pediatric dosing, preparation efficiency, and differentiated packaging rather than new-molecule exclusivity. The active ingredient is usually supplied as nafcillin sodium powder for injection, with limited excipient complexity and no conventional oral product opportunity.

What is the current pharmaceutical form of nafcillin?

Nafcillin is marketed primarily as nafcillin sodium for injection. The product is reconstituted with a compatible diluent and administered intravenously. Depending on the presentation, products may be supplied in single-dose vials, pharmacy bulk packages, or premixed infusion systems.

Attribute	Nafcillin profile
Active ingredient	Nafcillin sodium
Therapeutic class	Penicillinase-resistant penicillin
Main use	Serious infections caused by susceptible methicillin-sensitive staphylococci
Primary route	Intravenous; intramuscular use may be available for some products
Common strengths	1 g and 2 g vial presentations are widely associated with injectable use
Dosage form	Sterile powder for reconstitution; selected premixed presentations may exist
Key formulation issue	Chemical stability after reconstitution and compatibility with infusion systems
Commercial channel	Hospitals, outpatient parenteral antimicrobial therapy, government procurement, group purchasing organizations

Nafcillin is commonly selected when clinicians require an intravenous antistaphylococcal beta-lactam. The product competes with oxacillin, cefazolin, and, in selected situations, broader-spectrum agents such as vancomycin. FDA labeling identifies nafcillin for infections caused by susceptible penicillinase-producing staphylococci, subject to culture and susceptibility data.[1]

What excipients are used in nafcillin injection?

Nafcillin powder-for-injection products can have a relatively simple excipient profile. The principal formulation component is nafcillin sodium itself. Some products contain no conventional inactive excipient in the dry cake or powder. Others may include pH-adjusting agents or formulation aids, depending on the manufacturer and presentation.

Typical excipient categories

Excipient category	Potential role	Commercial relevance
Sodium hydroxide or hydrochloric acid	pH adjustment during manufacture	Controls solubility and stability
Sodium chloride	Tonicity adjustment in liquid presentations	Relevant to ready-to-use infusion products
Water for injection	Reconstitution or liquid vehicle	Required for sterile parenteral processing
Buffering agents	pH control	May affect stability and infusion compatibility
Nitrogen or inert headspace gas	Oxygen reduction during filling	May reduce oxidative degradation
Container-closure components	Sterility and moisture protection	Important for powder stability and shelf life

The precise inactive-ingredient profile must be verified against the current product label for each presentation. Nafcillin is not a product where a large excipient platform is likely to create meaningful differentiation by itself. The stronger commercial strategy is to use excipients and packaging to improve stability, handling, administration time, and supply continuity.

What formulation problems must an excipient strategy solve?

The central formulation challenge is maintaining potency and sterility through reconstitution, storage, transport, and administration. Nafcillin products may be exposed to multiple temperature conditions in hospital pharmacies and outpatient infusion settings. Reconstituted solutions can have shorter usable periods than the unopened powder, and compatibility depends on the diluent, concentration, container, temperature, and storage duration.

Key technical targets

A differentiated nafcillin formulation should target:

1. Longer post-reconstitution stability.
2. Reduced particulate formation and discoloration.
3. Reliable dissolution with low agitation requirements.
4. Compatibility with common infusion solutions.
5. Lower risk of adsorption to tubing or infusion containers.
6. Reduced preparation time in hospital pharmacies.
7. Improved stability under refrigerated and controlled-room-temperature conditions.
8. Preservation of sterility across the intended in-use period.

The product must remain within the labeled potency and quality specifications after reconstitution. Excipients that improve stability but increase viscosity, osmolality, irritation, or infusion incompatibility would have limited commercial value.

What excipient technologies could differentiate nafcillin?

Buffer and pH-control systems

A carefully selected buffer can reduce pH drift during reconstitution and storage. The buffer must not accelerate beta-lactam degradation or produce precipitation with common infusion fluids. A low-buffer or buffer-free approach may be preferable if the sodium salt already provides adequate pH control.

Commercial value is highest when the formulation supports a longer labeled in-use period without requiring complex pharmacy controls.

Tonicity modifiers

For ready-to-use liquid nafcillin, sodium chloride or another tonicity modifier may be needed to produce an acceptable infusion solution. The strategy must account for the sodium load, especially in patients receiving high daily doses or multiple sodium-containing medicines.

A low-sodium presentation could have value in intensive-care, renal, and pediatric settings, but the product would need to maintain acceptable osmolality and infusion tolerability.

Antioxidant systems

Oxidative degradation control may involve oxygen minimization, inert-gas filling, light protection, or selected antioxidants. Antioxidants require particular caution in injectable products because of impurity formation, regulatory scrutiny, compatibility, and potential hypersensitivity concerns.

For nafcillin, packaging and manufacturing controls may be more commercially attractive than adding an antioxidant excipient.

Bulking agents and cake-forming excipients

A lyophilized nafcillin product could use a bulking agent to improve cake structure, fill uniformity, and reconstitution performance. Suitable materials may include commonly used parenteral bulking excipients, subject to compatibility and regulatory support.

The commercial benefit would be greatest for low-dose or concentrated presentations, but standard nafcillin vial strengths may not require a complex lyophilization platform.

Surfactants

Surfactants may reduce wetting problems or adsorption in liquid systems. Their use should be limited because injectable surfactants can create extractables, aggregation, foaming, and tolerability concerns. A surfactant-based strategy is more likely to support a specific container or delivery system than to provide broad product differentiation.

What formulations are commercially protected or patentable?

Nafcillin has been marketed for decades, and the active compound itself is unlikely to provide meaningful new patent protection. Commercially relevant protection would more likely arise from:

• A stable liquid nafcillin formulation.
• A specific buffer and pH range.
• A defined concentration with extended room-temperature stability.
• A premixed infusion bag with validated container compatibility.
• A lyophilized cake with rapid reconstitution.
• A dual-chamber container separating nafcillin from the diluent.
• A low-sodium formulation.
• A pediatric-ready concentration.
• A container-closure system that limits moisture or oxygen exposure.
• A manufacturing process that reduces degradation impurities.
• A method of extending the post-reconstitution administration window.

A formulation patent would need claims that distinguish over established nafcillin sodium injection products and prior art involving other beta-lactam antibiotics. Broad claims covering nafcillin in water, saline, or standard buffers would face substantial obviousness and enablement risk.

How strong is the patent estate for nafcillin?

The nafcillin patent estate is commercially weak at the active-ingredient level because the molecule is old and generic competition is established. Any meaningful exclusivity would likely depend on a narrow formulation, delivery, manufacturing, or device claim.

IP area	Expected strength	Commercial implication
Original compound patent	Very low	Likely expired
Basic nafcillin sodium injection	Very low	Generic competition expected
New liquid formulation	Moderate if stability is unusual	Potential formulation exclusivity
Premixed infusion system	Moderate	Device and formulation claims may combine
Pediatric ready-to-use product	Moderate	Regulatory and market differentiation
Manufacturing impurity-control process	Moderate to high if difficult to reproduce	Potential supply and quality advantage
Method-of-use patent	Low to moderate	Limited value if directed to routine antibiotic treatment
Packaging or container patent	Low to moderate	Useful as part of a broader product estate

Patent protection would need to be assessed against current USPTO records, FDA Orange Book listings, and jurisdiction-specific registers. Historical generic injectable antibiotics often have little or no meaningful Orange Book patent blocking after launch.

What is the FDA regulatory status of nafcillin?

Nafcillin sodium injection is an FDA-recognized prescription antibacterial product available through approved injectable drug applications, including generic pathways. The product is not a biologic, so biosimilar regulation does not apply. Generic applicants generally pursue an abbreviated new drug application demonstrating pharmaceutical equivalence, bioequivalence where applicable, and compliance with injectable product quality requirements.

FDA requirements center on:

• Sterility assurance.
• Endotoxin control.
• Particulate matter.
• Strength and identity.
• Reconstitution performance.
• Stability and degradation products.
• Container-closure integrity.
• Manufacturing-process validation.
• Compatibility with labeled diluents and administration systems.

The FDA Orange Book remains the primary source for current approved applications, therapeutic-equivalence codes, patent listings, and regulatory exclusivity information.[2] For a legacy injectable such as nafcillin, market entry is more likely to be constrained by manufacturing capacity, inspection history, shortage conditions, and procurement access than by new chemical entity exclusivity.

When does nafcillin lose exclusivity?

Nafcillin’s original drug exclusivity and compound patent protection have expired. The commercial market is therefore generally open to approved generic manufacturers, subject to FDA approval and product supply capability.

Exclusivity category	Nafcillin position
New chemical entity exclusivity	Expired
Original compound patent	Expired
Pediatric exclusivity	Not a current commercial barrier
Orphan-drug exclusivity	Not generally applicable
Biosimilar reference-product exclusivity	Not applicable
Formulation exclusivity	Possible only for a newly approved differentiated product
Generic first-filer exclusivity	Could arise for a specific ANDA situation, subject to Orange Book and FDA records

A new nafcillin formulation could receive limited regulatory exclusivity only if it qualified under the applicable FDA pathway. Patent protection would be more important than regulatory exclusivity for a long-term commercial strategy.

What generic entry risks exist for nafcillin?

Generic entry risk is high for conventional powder-for-injection products because the active ingredient is established and the formulation is relatively simple. A new entrant could compete through a lower-cost vial, contract manufacturing, or hospital-contract pricing.

Risk is lower for differentiated products that solve operational problems:

• Ready-to-use bags.
• Longer refrigerated or room-temperature stability.
• Small-volume pediatric bags.
• Pharmacy bulk containers.
• Dual-chamber reconstitution systems.
• Improved supply reliability.
• Integrated barcode and preparation instructions.
• Contracted outpatient infusion products.

The main competitive threat to a differentiated product is not a direct copy of an excipient system. It is substitution with cefazolin or oxacillin, which may have stronger hospital familiarity, different dosing schedules, or more favorable procurement economics.

How does nafcillin compare with oxacillin and cefazolin?

Factor	Nafcillin	Oxacillin	Cefazolin
Drug class	Penicillinase-resistant penicillin	Penicillinase-resistant penicillin	First-generation cephalosporin
Main use	MSSA and susceptible staphylococcal infections	MSSA and susceptible staphylococcal infections	MSSA, skin infections, surgical prophylaxis
Typical administration burden	Frequent dosing or continuous-infusion strategies	Frequent dosing	Often less frequent dosing
Excipient opportunity	Ready-to-use and stability products	Similar injectable strategy	Stronger established premix opportunity
Substitution risk	High	High	High in many hospital protocols
Patent barrier	Low	Low	Low for legacy products
Commercial differentiation	Supply, handling, pediatric and OPAT formats	Similar	Convenience and dosing frequency

Cefazolin can be a strong commercial substitute because dosing and hospital workflow may be simpler in selected infections. A nafcillin product must therefore compete on clinical appropriateness, supply reliability, total preparation cost, and compatibility with outpatient infusion programs.

Which commercial opportunities exist for nafcillin?

Ready-to-use intravenous bags

A ready-to-use product can eliminate pharmacy reconstitution and reduce preparation errors. The main technical barriers are liquid stability, container compatibility, concentration, refrigerated distribution, and allowable room-temperature exposure.

The strongest target customers are hospitals with high antibiotic preparation volumes and outpatient parenteral antimicrobial therapy providers.

Extended-stability pharmacy products

A vial with improved reconstitution and longer in-use stability can reduce waste. This opportunity is valuable when hospitals frequently discard partially used or expired reconstituted doses.

The product can be differentiated without introducing a complex excipient system if the improvement comes from lyophilization, moisture control, oxygen management, or optimized fill-finish processing.

Pediatric and neonatal presentations

Small-volume, ready-to-administer products could address dosing and dilution problems in children and neonates. Commercial development would require careful control of concentration, preservative status, osmolality, sodium exposure, and dosing flexibility.

A preservative-free presentation is generally preferable for neonatal and pediatric use, although it increases container-closure and microbiological-control requirements.

Outpatient infusion and continuous-infusion systems

Nafcillin is used in some outpatient intravenous antibiotic programs. A product compatible with ambulatory pumps, elastomeric devices, or continuous-infusion protocols could generate value if stability is demonstrated under actual device and temperature conditions.

The relevant IP could include concentration, buffer system, pump compatibility, and storage protocol claims.

Hospital shortage and supply-resilience products

Legacy injectable antibiotics can experience supply disruptions because few manufacturers produce sterile beta-lactam products at commercial scale. A manufacturer with reliable capacity, dual-source raw materials, and strong quality performance could obtain hospital contracts even without patent exclusivity.

The commercial advantage would come from procurement reliability rather than molecule ownership.

What manufacturing and IP barriers affect nafcillin?

The primary barriers are sterile manufacturing, beta-lactam segregation, validated cleaning, containment, and regulatory compliance. Penicillin production requires controls to prevent cross-contamination and occupational exposure. These requirements can make manufacturing more difficult than the simple excipient list suggests.

Key barriers include:

• Dedicated or appropriately segregated beta-lactam manufacturing areas.
• Control of penicillin cross-contamination.
• Sterile powder filling.
• Moisture-sensitive packaging.
• Low particulate burden.
• Container-closure integrity.
• Validated reconstitution and stability methods.
• Reliable supply of pharmaceutical-grade nafcillin sodium.
• Consistent impurity profile across batches.

A defensible commercial position could combine a formulation patent with process know-how, validated stability data, device compatibility, and hospital purchasing contracts. A formulation patent alone would offer limited protection if the product can be designed around the claimed excipient ratios or concentration.

What licensing opportunities exist for nafcillin?

Licensing opportunities are more likely to involve platform technologies than the nafcillin molecule. Potential structures include:

Licensing target	Value proposition
Ready-to-use parenteral platform	Applies liquid-stability technology to nafcillin
Dual-chamber container	Separates drug and diluent until administration
Ambulatory infusion device	Enables outpatient or continuous infusion
Lyophilization technology	Improves reconstitution and shelf life
Sterile beta-lactam manufacturing	Provides capacity to a branded or generic sponsor
Hospital distribution partnership	Secures group purchasing and institutional access
Pediatric formulation platform	Supports low-volume, preservative-free presentations

A licensee would likely prioritize a platform with existing FDA-approved injectable products, transferable stability data, and an established fill-finish site. Nafcillin alone is unlikely to justify a major upfront payment unless the technology also applies to oxacillin, piperacillin, penicillin G, or other sterile beta-lactams.

What is the revenue exposure and competitive outlook?

Nafcillin is a mature generic product with limited molecule-level pricing power. Revenue exposure depends on hospital volume, contract status, shortage conditions, and product presentation. A conventional vial is likely to face price competition. A ready-to-use or pediatric product could command a premium if it reduces labor, waste, and medication-preparation risk.

The most attractive commercial model is a differentiated injectable portfolio that includes nafcillin alongside other hospital antibiotics. This spreads regulatory, manufacturing, and sales costs across multiple products and reduces dependence on a single legacy molecule.

Key Takeaways

• Nafcillin is primarily an injectable generic antibiotic with expired compound-level exclusivity.
• The strongest commercial opportunities involve ready-to-use bags, extended post-reconstitution stability, pediatric presentations, outpatient infusion, and supply reliability.
• Excipient selection should focus on pH control, tonicity, oxygen management, reconstitution, and container compatibility.
• A simple powder-for-injection product has limited patent and pricing strength.
• Formulation, device, manufacturing, and process claims offer the most credible IP pathways.
• Generic entry risk is high for conventional vials and lower for technically differentiated presentations.
• Cefazolin and oxacillin are important commercial substitutes.
• The largest manufacturing barriers are sterile beta-lactam handling, segregation, fill-finish control, and stability validation.
• A nafcillin license is more attractive as part of a broader injectable-antibiotic platform than as a standalone molecule transaction.

FAQs

Can nafcillin be formulated as a ready-to-use infusion?

Yes. A ready-to-use product would require validated liquid stability, container compatibility, acceptable osmolality, sterility assurance, and defined storage conditions. The commercial benefit would be reduced pharmacy preparation and lower product waste.

Is nafcillin compatible with elastomeric infusion pumps?

Compatibility cannot be assumed from vial reconstitution data. A commercial product would require device-specific studies covering concentration, temperature, contact time, adsorption, potency, degradation, and particulate formation.

Could a low-sodium nafcillin formulation be commercially differentiated?

Potentially. A low-sodium formulation could target patients receiving high-dose therapy or multiple sodium-containing products. The formulation would need to preserve stability and acceptable infusion characteristics while reducing total sodium exposure.

Are preservatives appropriate for pediatric nafcillin injections?

A preservative-free presentation is generally more attractive for neonatal and pediatric use. Multidose preservative-containing systems would require a specific clinical and regulatory rationale, with careful assessment of tolerability and dosing population.

Can a new nafcillin excipient combination receive patent protection?

Possibly, but the claims would need a defensible technical effect, such as unexpected stability, reduced impurities, improved reconstitution, or validated device compatibility. Broad claims covering routine buffers, saline, or standard injectable excipients would face substantial prior-art risk.

References

1. DailyMed. (n.d.). Nafcillin sodium injection prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (n.d.). Container closure systems for packaging human drugs and biologics: Chemistry, manufacturing, and controls documentation. https://www.fda.gov/

5. U.S. Pharmacopeia. (n.d.). General chapters for sterile pharmaceutical preparations, injectable products, and particulate matter. United States Pharmacopeial Convention. https://www.usp.org/